Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
50 hedge funds and large institutions have $9.09M invested in Clearside Biomedical in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 12 closing their positions.
52% more call options, than puts
Call options by funds: $149K | Put options by funds: $98K
0.06% less ownership
Funds ownership: 1.01% → 0.95% (-0.06%)
6% less funds holding
Funds holding: 53 → 50 (-3)
11% less capital invested
Capital invested by funds: $10.2M → $9.09M (-$1.14M)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$129K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$84.1K |
| 3 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$32.6K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$27.2K |
| 5 |
WIC
Water Island Capital
New York
|
+$23.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$166K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$85.9K |
| 3 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$73K |
| 4 |
Two Sigma Investments
New York
|
-$72.9K |
| 5 |
Two Sigma Advisers
New York
|
-$67.1K |
CLSD Hedge Fund Activity: Q1 2023 in Review
50 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2023, worth a combined $9.09M — down 11% from $10.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CLSD and 9 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was Janney Montgomery Scott, opening a new position worth an estimated $129K. The largest seller was Renaissance Technologies, cutting an estimated $166K.
- 50 institutional investors held Clearside Biomedical (CLSD) as of Q1 2023, down from 53 in Q4 2022.
- Funds reported $9.09M of Clearside Biomedical stock for Q1 2023, down 11% quarter-over-quarter.
- 9 funds opened new Clearside Biomedical positions in Q1 2023 and 12 closed out, a net change of -3 holders.
- The largest Clearside Biomedical buyer in Q1 2023 was Janney Montgomery Scott, an estimated $129K added.
- The largest Clearside Biomedical seller in Q1 2023 was Renaissance Technologies, an estimated $166K sold.
Based on aggregated 13F filings for Q1 2023.